It is recommended that streamlined management pathways be established for these patients, centered on the following: 1) Safe medication use: It is imperative to closely monitor and enhance surveillance for the emergence of acute kidney injury, hypovolemia, and hyperkalemia when administering SGLT2 inhibitors in conjunction with NSAIDs or ACEI/ARBs (91). This evidence concerns the gene SLC5A2 and Hyperkalemia.